It was pointed out that one of the key issues with therapeutic proteins, which is primarily what the companies at Accelerator are developing is that they are not usually orally bioavailable. So they end up having to be injectables. And injections are - ...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
